Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05155345 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT05155345 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 15 participants.
The verdict
NCT05155345, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mosunetuzumab in participants with systemic lupus erythematosus (SLE).
Interventions
- DRUG Mosunetuzumab
- DRUG Tocilizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-01-11 |
| Est. Completion | 2024-12-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05155345
The ClinicalTrials.gov registry entry for NCT05155345 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mosunetuzumab is the first listed.
NCT05155345 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05155345 about?
NCT05155345 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus". This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mosunetuzumab in participants with systemic lupus erythematosus (SLE).
What is the current status of trial NCT05155345?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2022-01-11. Estimated completion is 2024-12-17.
What interventions are being tested in trial NCT05155345?
The interventions under investigation include: Mosunetuzumab (DRUG), Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT05155345?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.